The PET tracer landscape is becoming increasingly dynamic, especially in the US, where the infrastructure is quite mature versus other regions which still rely mostly on SPECT. The development and success of prostate-specific membrane antigen tracers over the past years underscores the clinical promise of sensitive and specific images the modality brings. Plus, the evolution of guidelines towards broader use in patient staging will likely fuel adoption even more.

Beyond prostate cancer, central nervous systems applications are gaining traction and the cardiac space saw the recent approval of a new tracer. In fact, a wide number of new targets are under investigation across numerous therapeutic areas. These developments showcase that the true potential of PET imaging applications is just starting to develop in an environment shifting towards personalized medicine.

The PET radiotracer market poses challenges from many angles. Competition is multi-faceted and intense due to the wide range of modalities which also show continuous improvement, e.g., magnetic resonance. Some therapeutic areas are accustomed to more established imaging techniques, such as SPECT in cardiac indications, which might initially slow down PET adoption. Novel tracer price points are on the higher end, raising additional market access considerations. Additionally, due to the specific nature of nuclear medicine and isotopes’ half-life, companies need to master logistics and value chain aspects to ensure effective product supply and adoption.

Companies can stand out in multiple ways. Obviously, for PET tracer developers, clinical performance is a priority to ensure patients receive the best imaging possible. Therefore, some keys to success include investigating highly specific targets which are relevant for imaging purposes, improving chelation, or leveraging the relevant isotope.

Supply chain command, whether direct or indirect, is crucial to foster product adoption given the importance of logistics control, e.g., appropriate radiopharmacy coverage and distribution. And as markets mature, an effective commercial and pricing strategy is instrumental in facing evolving payer coverage schemes and retaining market share.

From a clinical development standpoint, new compounds leveraging radiohybrid ligands could unlock higher affinity, while also leaving room for therapeutic isotope radiolabeling. Several isotopes such as Cu-64 or Pb-203 might see uptake in the future due to their pairing feature with their therapeutic counterpart.

On the logistics side, some enablers are investing in capital equipment uplift, e.g., higher capacity Ga-68 generators to address increased demand and extend Ga-68 tracers’ shelf life. Consolidation and value chain integration are additional dynamics impacting the competitive landscape, creating higher interdependencies and reshaping incumbent interactions for years to come. Companies should always look out for potential disruption emerging from new targets and isotopes, innovative ways to improve PET imaging access, and strategic moves to integrate more steps of the value chain.

I’m quite optimistic about the future of this field. The trend is for continuous and expanded use of PET imaging, whether in new therapeutic areas or within the same indication for more patient subsets. Investment in infrastructure, such as cyclotrons for isotope production, will help cope with the expected increasing demand. Incumbents that develop PET agents to deliver on the modality’s clinical promise will find success, especially if tracers are also accessible and supplied as seamlessly as possible despite intrinsic logistical limitations.